Delfi Diagnostics, Inc. is a biotechnology company based in Baltimore, Maryland, that focuses on the early detection of cancer through non-invasive blood tests. Founded in 2018, the company utilizes advanced technologies such as artificial intelligence and genome sequencing to identify unique patterns of DNA fragmentation in patients' blood. By leveraging machine learning, Delfi develops innovative testing systems aimed at recognizing cancer-associated cell-free DNA fragments, thereby enabling healthcare professionals to detect cancer at its most treatable stage. This approach facilitates timely and effective treatment options, ultimately aiming to improve patient outcomes and recovery speed.
Developer of medical test products designed to transform the detection and treatment of cancer and other complex diseases. The company's products leverage proteomic data to complement extensive proteomic information with genomic, metabolomic and other health data and discover innovative approaches to early disease detection that translate into transformative test products, enabling medical practitioners to improve diagnostic tests and recurrence monitoring of critical diseases.
RefleXion Medical Inc. specializes in developing a biologically-guided radiotherapy system aimed at transforming cancer treatment. The company’s innovative technology allows tumors to continuously signal their location during therapy, facilitating the simultaneous treatment of multiple tumors, particularly in cases of metastasis. The RefleXion X1 machine is currently cleared for various forms of radiotherapy, including stereotactic body radiotherapy (SBRT) and intensity-modulated radiotherapy (IMRT). At the core of RefleXion's approach is the integration of positron-emission tomography (PET) imaging, which enables real-time tumor tracking and dose adaptation based on the biological characteristics of the tumors. This advancement in radiotherapy promises to enhance precision in cancer treatment, offering a potential paradigm shift in radiation oncology. RefleXion Medical, incorporated in 2009 and based in Hayward, California, has established strategic collaborations, including partnerships with Telix Pharmaceuticals and HealthMyne.
Eikon Therapeutics is a biopharmaceutical company focused on developing innovative treatments for chronic and life-threatening diseases. Founded in 2019 and based in Hayward, California, the company utilizes advanced super-resolution microscopy technology to conduct live-cell and single-molecule imaging. This cutting-edge approach allows for real-time, molecular-resolution measurements of protein movement within living cells, enabling the identification of previously intractable drug targets. By directly measuring the interactions between chemical compounds and individual proteins in a cellular environment, Eikon Therapeutics aims to unlock new avenues for drug discovery and address complex health challenges.
Freenome, Inc., is an artificial intelligence (AI) genomics biotech company. The company develops and provides a medical arti?cial intelligence platform for early detection of cancer. It develops blood tests for early-cancer screening and treatment selection. The company also provides clinical research services. Freenome, Inc. was founded in 2014 and is based in South San Francisco, California.
Chroma Medicine is a genomic medicine company focused on epigenetic editing to transform the treatment of genetically driven diseases. By leveraging epigenetics, which regulates gene expression naturally, Chroma Medicine aims to develop innovative therapies that provide precise control over gene activity. The company utilizes programmable epigenetic editors that combine DNA binding domains with epigenetic effector domains, allowing for targeted manipulation of genes and chromatin structure. This approach promises to create a new class of therapeutics that offers unparalleled control over gene expression, potentially leading to more effective treatments for a range of genetic disorders.
Arbor Biotechnologies operator of a bio-discovery company intended to provide human diagnostic development service. The company's platform employs a diverse set of technologies and techniques including artificial intelligence, genome sequencing, gene synthesis and high-throughput screening, enabling drug developers to accelerate the discovery of proteins for improving human health and sustainability.
Honor Technology, Inc. operates an online platform that connects in-home caregivers with seniors and their families across several states, including California, Texas, New Mexico, Arizona, Ohio, and Michigan. Founded in 2014 and based in San Francisco, the company provides non-medical home care services aimed at helping older adults live safely and comfortably in their own homes. Honor leverages proprietary technology to screen and match caregivers with seniors based on their specific needs. The platform offers features such as the Honor Frame, which informs seniors about their caregivers and arrival times. Additionally, families can monitor caregiver activities and visit durations. By partnering with local agencies through the Honor Care Network, the company enhances caregiver recruiting, training, and scheduling, supporting a reliable and transparent care experience for older adults.
SomaLogic operates as a protein biomarker discovery and clinical diagnostics company. It offers SOMAmers (Slow-Offrate Modified Aptamers), which are modified nucleic acid-based protein-binding reagents that are specific for their cognate protein; and SOMAscan that provides protein detection and equipment. The company’s SOMAmer/SOMAscan technology enables to discover protein biomarker signatures; drug discovery and development; and clinical diagnostics. Its products have applications in the diagnostics of various diseases in oncology, neurology, cardiovascular and metabolic disease, and other diseases and conditions.
SomaLogic was founded in 1999 and is headquartered in Boulder, Colorado.
Sema4 is a patient-centered predictive health company dedicated to advancing the diagnosis, treatment, and prevention of disease. With their innovative Sema4 Health Intelligence Platform, they’re using advanced network analysis to build better models of human health and deliver personalized insights for patients.
Element Biosciences, Inc. develops genetic analysis tools for the research and diagnostic markets. The company provides a disruptive DNA sequencing technology and a sequencing platform, such as surface chemistry, sequencing chemistry, detection, and data analysis. The company was incorporated in 2017 and is based in San Diego, California.
Clear Labs, Inc. is a food analytics company based in Menlo Park, California, founded in 2013. The company offers a comprehensive food analytics platform that utilizes next-generation sequencing to analyze the molecular contents of foods and ingredients. This platform provides food manufacturers, suppliers, and retailers with crucial transparency across supply chains, testing products for authenticity, contaminants, allergens, and various other factors such as GMOs, heavy metals, and nutrition. Clear Labs also focuses on simplifying complex diagnostics for clinical and applied markets, combining DNA sequencing, robotics, and cloud-based analytics to improve accuracy and accelerate outcomes. By delivering insights into food safety and quality, Clear Labs aims to enhance understanding and management of potential health risks associated with food products and emerging pathogens.
Private Equity Round in 2021
Caris Life Sciences is a biotechnology company based in Irving, Texas, specializing in precision medicine and cancer treatment. Founded in 1996, the company develops and commercializes advanced diagnostic technologies, including anatomic pathology and molecular profiling, to enhance the understanding of cancer biology. Its services encompass comprehensive molecular analyses of patient samples, integrating genomic, transcriptomic, and proteomic profiling through the Caris Molecular Intelligence platform. This platform aids physicians and cancer patients in making informed and personalized treatment decisions by revealing the molecular blueprint of complex diseases. Caris Life Sciences serves a global customer base through distributors in regions including the United States, Europe, and Australia, and maintains a strategic collaboration with Debiopharm International SA. The company is committed to improving patient outcomes through innovative scientific advancements and a focus on quality care.
Private Equity Round in 2021
Rapid Micro Biosystems provides products for the detection of microbial contamination in the manufacture of pharmaceutical, biotechnology, and personal care products. It offers the Growth Direct System, a non-destructive method for microbial enumeration.
The company was formerly known as Genomic Profiling Systems and changed its name to Rapid Micro Biosystems in 2007. Rapid Micro Biosystems was founded in 2006 and is based in Bedford, Massachusetts.
Vividion Therapeutics, Inc. is a biotechnology company based in San Diego, California, focused on developing therapeutics to address significant unmet medical needs. The company utilizes a novel platform for proteome-wide small molecule drug discovery, which combines proteomic techniques and synthetic chemistry to enhance drug selectivity and broaden the range of druggable proteins. Originating from research at The Scripps Research Institute, Vividion's technology enables the creation of detailed drug interaction maps, facilitating simultaneous target engagement and comprehensive selectivity profiling. By advancing its innovative synthetic and proteomic chemistry approaches, Vividion aims to deliver transformative treatments for patients with serious illnesses.
Design Therapeutics, Inc. is a clinical-stage biotechnology company based in Solana Beach, California, focused on developing innovative therapies for degenerative disorders resulting from nucleotide repeat expansions. Founded in 2017, the company is advancing its lead program aimed at treating Friedreich's ataxia, while also exploring treatment options for other conditions such as Fragile X syndrome and myotonic dystrophy. Design Therapeutics is known for its GeneTACTM molecules, a new class of small-molecule gene-targeted therapies designed to address the underlying causes of diseases linked to inherited nucleotide repeat expansion mutations. The company's ongoing research efforts seek to develop disease-modifying treatments for serious conditions driven by these genetic factors.
Private Equity Round in 2021
Kardium Inc. is a medical solutions company based in Burnaby, Canada, specializing in the diagnosis and treatment of atrial fibrillation (AF). Founded in 2007, the company has developed the Globe Mapping and Ablation System, which streamlines AF treatment by integrating single-shot pulmonary vein isolation, high-definition mapping, and atrial ablation into a single catheter. This advanced system aids medical practitioners in diagnosing and treating cardiovascular diseases by providing detailed electrophysiological mapping and the ability to ablate cardiac tissue using radio-frequency energy. Kardium's team comprises experts in medicine, engineering, and research, ensuring a robust foundation for innovation in medical device technology.
Delfi Diagnostics, Inc. is a biotechnology company based in Baltimore, Maryland, that focuses on the early detection of cancer through non-invasive blood tests. Founded in 2018, the company utilizes advanced technologies such as artificial intelligence and genome sequencing to identify unique patterns of DNA fragmentation in patients' blood. By leveraging machine learning, Delfi develops innovative testing systems aimed at recognizing cancer-associated cell-free DNA fragments, thereby enabling healthcare professionals to detect cancer at its most treatable stage. This approach facilitates timely and effective treatment options, ultimately aiming to improve patient outcomes and recovery speed.
Color is a population health technology company founded in 2014 and based in Burlingame, California. It focuses on providing technology and infrastructure for large-scale health initiatives, making advanced healthcare services accessible and cost-effective. Color's Population Genomics Platform offers modular and comprehensive solutions designed to help health systems, employers, and research institutions develop and implement effective population health programs. The company combines innovative technology with specialized laboratory infrastructure and clinical services, facilitating various aspects of health programs, including strategy, participant engagement, genetic testing, data management, and clinical reporting. Color’s partnerships with organizations such as the National Institutes of Health and Verily enhance its capabilities, enabling it to deliver precision health programs that address the challenges of traditional healthcare access and costs.
Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of clinical and molecular data, and an operating system to make that data accessible and useful, Tempus enables physicians to make real-time, data-driven decisions to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data.
SomaLogic operates as a protein biomarker discovery and clinical diagnostics company. It offers SOMAmers (Slow-Offrate Modified Aptamers), which are modified nucleic acid-based protein-binding reagents that are specific for their cognate protein; and SOMAscan that provides protein detection and equipment. The company’s SOMAmer/SOMAscan technology enables to discover protein biomarker signatures; drug discovery and development; and clinical diagnostics. Its products have applications in the diagnostics of various diseases in oncology, neurology, cardiovascular and metabolic disease, and other diseases and conditions.
SomaLogic was founded in 1999 and is headquartered in Boulder, Colorado.
Private Equity Round in 2020
Caris Life Sciences is a biotechnology company based in Irving, Texas, specializing in precision medicine and cancer treatment. Founded in 1996, the company develops and commercializes advanced diagnostic technologies, including anatomic pathology and molecular profiling, to enhance the understanding of cancer biology. Its services encompass comprehensive molecular analyses of patient samples, integrating genomic, transcriptomic, and proteomic profiling through the Caris Molecular Intelligence platform. This platform aids physicians and cancer patients in making informed and personalized treatment decisions by revealing the molecular blueprint of complex diseases. Caris Life Sciences serves a global customer base through distributors in regions including the United States, Europe, and Australia, and maintains a strategic collaboration with Debiopharm International SA. The company is committed to improving patient outcomes through innovative scientific advancements and a focus on quality care.
Honor Technology, Inc. operates an online platform that connects in-home caregivers with seniors and their families across several states, including California, Texas, New Mexico, Arizona, Ohio, and Michigan. Founded in 2014 and based in San Francisco, the company provides non-medical home care services aimed at helping older adults live safely and comfortably in their own homes. Honor leverages proprietary technology to screen and match caregivers with seniors based on their specific needs. The platform offers features such as the Honor Frame, which informs seniors about their caregivers and arrival times. Additionally, families can monitor caregiver activities and visit durations. By partnering with local agencies through the Honor Care Network, the company enhances caregiver recruiting, training, and scheduling, supporting a reliable and transparent care experience for older adults.
NeueHealth is a health care service platform that focuses on improving patient experiences and outcomes through a combination of technology and local healthcare resources. It operates 61 affiliated primary care clinics that deliver both virtual and in-person clinical care to nearly 75,000 unique patients. NeueHealth is part of Bright Health Group, which also offers Medicare and commercial health plan products to approximately 623,000 consumers across 14 states. The company aims to reduce healthcare costs while enhancing access and quality of care by aligning the interests of consumers, providers, and payers. Founded in 2015 and based in Minneapolis, Minnesota, NeueHealth leverages intelligent technology to connect users with healthcare services and providers effectively.
Developer of medical test products designed to transform the detection and treatment of cancer and other complex diseases. The company's products leverage proteomic data to complement extensive proteomic information with genomic, metabolomic and other health data and discover innovative approaches to early disease detection that translate into transformative test products, enabling medical practitioners to improve diagnostic tests and recurrence monitoring of critical diseases.
Freenome, Inc., is an artificial intelligence (AI) genomics biotech company. The company develops and provides a medical arti?cial intelligence platform for early detection of cancer. It develops blood tests for early-cancer screening and treatment selection. The company also provides clinical research services. Freenome, Inc. was founded in 2014 and is based in South San Francisco, California.
Thrive Earlier Detection Corp. is a healthcare company dedicated to improving cancer detection through innovative technology. It focuses on the development of CancerSEEK, a liquid biopsy test that analyzes genomic mutations in tumor DNA and protein markers in plasma to identify multiple types of cancer at their earliest stages, often before symptoms become apparent. Founded in 2018 and headquartered in Cambridge, Massachusetts, with an additional office in Baltimore, Maryland, Thrive aims to integrate early cancer detection into routine medical care. The company was previously known as Thrive Sciences Inc. and has been a subsidiary of Exact Sciences Corporation since early 2021. Thrive was launched with support from various investors, including Third Rock Ventures and Section 32, reflecting a strong commitment to advancing cancer diagnostics.
Seer, Inc. is a life sciences company that specializes in developing nanoparticle technology solutions aimed at advancing proteomics research. The company's flagship product, Proteograph, is an integrated system that includes consumables, automation instrumentation, and proprietary software designed for proteomics analysis. Seer targets academic institutions, life sciences research laboratories, and biopharmaceutical companies, offering its products for research purposes, specifically for non-diagnostic and non-clinical applications. Additionally, Seer has created a health data platform that enhances the early detection of chronic, life-threatening diseases by capturing and translating molecular insights from the proteome. This innovation aims to improve accuracy and speed in identifying conditions such as cancer and neurological diseases, ultimately facilitating earlier treatment and better patient outcomes. Headquartered in Redwood City, California, Seer was incorporated in 2017 and was previously known as Seer Biosciences, Inc. before its name change in July 2018.
RefleXion Medical Inc. specializes in developing a biologically-guided radiotherapy system aimed at transforming cancer treatment. The company’s innovative technology allows tumors to continuously signal their location during therapy, facilitating the simultaneous treatment of multiple tumors, particularly in cases of metastasis. The RefleXion X1 machine is currently cleared for various forms of radiotherapy, including stereotactic body radiotherapy (SBRT) and intensity-modulated radiotherapy (IMRT). At the core of RefleXion's approach is the integration of positron-emission tomography (PET) imaging, which enables real-time tumor tracking and dose adaptation based on the biological characteristics of the tumors. This advancement in radiotherapy promises to enhance precision in cancer treatment, offering a potential paradigm shift in radiation oncology. RefleXion Medical, incorporated in 2009 and based in Hayward, California, has established strategic collaborations, including partnerships with Telix Pharmaceuticals and HealthMyne.
Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of clinical and molecular data, and an operating system to make that data accessible and useful, Tempus enables physicians to make real-time, data-driven decisions to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data.
Alignment Healthcare is dedicated to transforming the complex and confusing process of medical treatment so that every link in the healthcare continuum becomes more efficient, productive and effective. The company partners with providers, health plans and hospitals to create a seamless, fast and easy-to-navigate healthcare experience, which results in happier, healthier and more satisfied patients. Based in Irvine, California, Alignment Healthcare provides partners with an end-to-end continuous care program, including clinical care coordination, risk management capabilities, and IT enablement
Outset Medical, Inc. is a medical technology company that specializes in developing advanced hemodialysis systems for both acute and chronic patient care. The company's flagship product, the Tablo Hemodialysis System, is a compact and user-friendly dialysis machine designed to provide efficient care in various settings. Tablo integrates essential features such as water purification, on-demand dialysate production, and connectivity capabilities, making it versatile and convenient for healthcare providers. With its wireless data transmission, sensor-based automation, and an intuitive animated touchscreen, Tablo aims to enhance the patient care experience while driving innovation in service models to reduce costs. Founded in 2003 and headquartered in San Jose, California, Outset Medical was previously known as Home Dialysis Plus, Ltd. until its rebranding in 2015.
Color is a population health technology company founded in 2014 and based in Burlingame, California. It focuses on providing technology and infrastructure for large-scale health initiatives, making advanced healthcare services accessible and cost-effective. Color's Population Genomics Platform offers modular and comprehensive solutions designed to help health systems, employers, and research institutions develop and implement effective population health programs. The company combines innovative technology with specialized laboratory infrastructure and clinical services, facilitating various aspects of health programs, including strategy, participant engagement, genetic testing, data management, and clinical reporting. Color’s partnerships with organizations such as the National Institutes of Health and Verily enhance its capabilities, enabling it to deliver precision health programs that address the challenges of traditional healthcare access and costs.
Seer, Inc. is a life sciences company that specializes in developing nanoparticle technology solutions aimed at advancing proteomics research. The company's flagship product, Proteograph, is an integrated system that includes consumables, automation instrumentation, and proprietary software designed for proteomics analysis. Seer targets academic institutions, life sciences research laboratories, and biopharmaceutical companies, offering its products for research purposes, specifically for non-diagnostic and non-clinical applications. Additionally, Seer has created a health data platform that enhances the early detection of chronic, life-threatening diseases by capturing and translating molecular insights from the proteome. This innovation aims to improve accuracy and speed in identifying conditions such as cancer and neurological diseases, ultimately facilitating earlier treatment and better patient outcomes. Headquartered in Redwood City, California, Seer was incorporated in 2017 and was previously known as Seer Biosciences, Inc. before its name change in July 2018.
Freenome, Inc., is an artificial intelligence (AI) genomics biotech company. The company develops and provides a medical arti?cial intelligence platform for early detection of cancer. It develops blood tests for early-cancer screening and treatment selection. The company also provides clinical research services. Freenome, Inc. was founded in 2014 and is based in South San Francisco, California.
Private Equity Round in 2019
Kardium Inc. is a medical solutions company based in Burnaby, Canada, specializing in the diagnosis and treatment of atrial fibrillation (AF). Founded in 2007, the company has developed the Globe Mapping and Ablation System, which streamlines AF treatment by integrating single-shot pulmonary vein isolation, high-definition mapping, and atrial ablation into a single catheter. This advanced system aids medical practitioners in diagnosing and treating cardiovascular diseases by providing detailed electrophysiological mapping and the ability to ablate cardiac tissue using radio-frequency energy. Kardium's team comprises experts in medicine, engineering, and research, ensuring a robust foundation for innovation in medical device technology.
Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of clinical and molecular data, and an operating system to make that data accessible and useful, Tempus enables physicians to make real-time, data-driven decisions to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data.
Home Dialysis Plus, Ltd. provides home hemodialysis solutions to patients and their healthcare providers. Its dialysis system enables hemodialysis treatment in the homes of patients. Home Dialysis Plus, Ltd. was founded in 2003 and is based in Portland, Oregon.
Outset Medical, Inc. is a medical technology company that specializes in developing advanced hemodialysis systems for both acute and chronic patient care. The company's flagship product, the Tablo Hemodialysis System, is a compact and user-friendly dialysis machine designed to provide efficient care in various settings. Tablo integrates essential features such as water purification, on-demand dialysate production, and connectivity capabilities, making it versatile and convenient for healthcare providers. With its wireless data transmission, sensor-based automation, and an intuitive animated touchscreen, Tablo aims to enhance the patient care experience while driving innovation in service models to reduce costs. Founded in 2003 and headquartered in San Jose, California, Outset Medical was previously known as Home Dialysis Plus, Ltd. until its rebranding in 2015.
RefleXion Medical Inc. specializes in developing a biologically-guided radiotherapy system aimed at transforming cancer treatment. The company’s innovative technology allows tumors to continuously signal their location during therapy, facilitating the simultaneous treatment of multiple tumors, particularly in cases of metastasis. The RefleXion X1 machine is currently cleared for various forms of radiotherapy, including stereotactic body radiotherapy (SBRT) and intensity-modulated radiotherapy (IMRT). At the core of RefleXion's approach is the integration of positron-emission tomography (PET) imaging, which enables real-time tumor tracking and dose adaptation based on the biological characteristics of the tumors. This advancement in radiotherapy promises to enhance precision in cancer treatment, offering a potential paradigm shift in radiation oncology. RefleXion Medical, incorporated in 2009 and based in Hayward, California, has established strategic collaborations, including partnerships with Telix Pharmaceuticals and HealthMyne.
Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of clinical and molecular data, and an operating system to make that data accessible and useful, Tempus enables physicians to make real-time, data-driven decisions to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data.
Quanterix Corporation is a life sciences company focused on developing an advanced platform for single-molecule analysis, known for its ultra-sensitive digital immunoassay technology. This innovative approach enables precise detection and quantification of individual proteins and small molecules in complex biological samples, which is critical for clinical diagnostics, drug development, and life science research. Quanterix's flagship technology, Simoa, allows for the reliable measurement of protein biomarkers in extremely low concentrations, surpassing conventional immunoassay methods. The company offers a range of products, including assay kits, specialized assays for neurodegenerative diseases, and advanced instrumentation designed to enhance early disease detection and improve patient outcomes. Founded in 2007, Quanterix is supported by prominent life science investors, positioning it to address significant unmet medical needs and contribute to advancements in healthcare.
Guardant Health, Inc. is a precision oncology company based in Redwood City, California, specializing in liquid biopsy tests and analytics for cancer detection and treatment. The company provides advanced testing solutions, including Guardant360, a molecular diagnostic test that analyzes numerous cancer-related genes, and GuardantOMNI, which offers a comprehensive gene panel for immuno-oncology research. Additionally, Guardant Health has developed LUNAR-1 for detecting minimal residual disease in cancer survivors and is working on LUNAR-2 for early cancer detection in high-risk individuals. The company also supports biopharmaceutical companies and medical institutions by offering companion diagnostic development, clinical trial referrals, and liquid biopsy testing services. Guardant Health's innovations aim to address unmet needs in oncology and enhance patient health through advanced technology and research collaborations. The company was incorporated in 2011 and continues to lead in liquid-based cancer testing for both clinical and research applications.
Outset Medical, Inc. is a medical technology company that specializes in developing advanced hemodialysis systems for both acute and chronic patient care. The company's flagship product, the Tablo Hemodialysis System, is a compact and user-friendly dialysis machine designed to provide efficient care in various settings. Tablo integrates essential features such as water purification, on-demand dialysate production, and connectivity capabilities, making it versatile and convenient for healthcare providers. With its wireless data transmission, sensor-based automation, and an intuitive animated touchscreen, Tablo aims to enhance the patient care experience while driving innovation in service models to reduce costs. Founded in 2003 and headquartered in San Jose, California, Outset Medical was previously known as Home Dialysis Plus, Ltd. until its rebranding in 2015.
Home Dialysis Plus, Ltd. provides home hemodialysis solutions to patients and their healthcare providers. Its dialysis system enables hemodialysis treatment in the homes of patients. Home Dialysis Plus, Ltd. was founded in 2003 and is based in Portland, Oregon.
Dr. Lal PathLabs, founded in 1949 by Dr. S.K. Lal, a pioneer in pathology, has established itself as a leading clinical pathology laboratory in India. Originally the first of its kind in Delhi and Northern India, the organization has expanded its services to include comprehensive diagnostic offerings in pathology and radiology. Dr. Lal PathLabs operates multiple laboratories that conduct a wide range of tests across various disciplines such as biochemistry, hematology, histopathology, microbiology, immunology, and virology. These diagnostic services play a crucial role in disease prevention, monitoring, and treatment, ultimately contributing to improved health outcomes. While the company primarily generates its revenue in India, it also operates in several other countries, reflecting its growing international presence in the healthcare sector.
Advanced Accelerator Applications (AAA), is a European Pharmaceutical Group founded in 2002 by Italian academics as a spin-off of the “European Organization for Nuclear Research” (CERN), Geneva, Switzerland), to develop innovative diagnostic and therapeutic products.
AAA’s main focus is in the field of Molecular Imaging and targeted, individualized therapy for the management of patients with serious conditions (Personalized Medicine).
AAA is a European leader in the production and commercialization of PET (Positron Emission Tomography) radiopharmaceuticals. PET is a state-of-the-art diagnostic technique that is today mainly used in clinical oncology, cardiology and neurology. AAA also produces a broad range of SPECT products.
AAA currently has 17 production and R&D facilities able to manufacture both diagnostics and therapeutic MNM products, and has over 300 employees in 11 countries (France, Italy, UK, Germany, Switzerland, Spain, Poland, Portugal, Israel, United States and Canada).
Advaxis, Inc. is a clinical-stage biotechnology company based in Princeton, New Jersey, focused on developing immunotherapies for cancer and infectious diseases. The company utilizes a unique platform based on live, attenuated bacteria engineered to deliver antigen/adjuvant fusion proteins, which aim to enhance the immune response against cancer. Advaxis is actively developing therapies for HPV-related cancers, including axalimogene filolisbac, currently in a Phase II clinical trial for head and neck cancer. Other products in development include ADXS-PSA for prostate cancer, ADXS-NEO for individualized treatment using neoantigens from a patient’s tumor, ADXS-HOT for generating robust anti-cancer immunity, and ADXS-HER2 targeting HER2-positive tumors. Advaxis has established collaborations and licensing agreements with various organizations to further advance its research and development efforts. The company was founded in 2002 and continues to progress its innovative treatments through multiple clinical trials.
Doximity is a digital platform that serves as the largest professional medical network in the United States, connecting over 70 percent of U.S. physicians. Founded in 2011 and based in San Francisco, Doximity provides a suite of tools designed specifically for medical professionals, including physicians, nurse practitioners, physician assistants, and registered nurses. The platform facilitates secure communication among healthcare providers, enabling them to collaborate on patient care, conduct virtual visits, and stay informed about the latest medical news and research. Additionally, Doximity offers resources to help medical professionals manage their careers effectively.
Castlight Health is dedicated to simplifying the healthcare experience and promoting healthier, more productive lives. Its health navigation platform integrates with various health vendors, benefits resources, and plan designs, creating a comprehensive application that addresses diverse health needs. By tailoring guidance to individual profiles, Castlight assists users, whether they are healthy, managing chronic conditions, or seeking medical care, in accessing optimal resources. The company aims to help organizations manage rising healthcare costs and enhance the value of their benefits investments. Since its inception, Castlight has introduced innovative solutions such as data-driven price transparency tools and a consumer-friendly wellbeing platform. Currently, it serves millions of users and partners with numerous large employers, positioning itself as a key player in the healthcare sector. Castlight is headquartered in San Francisco.